论文部分内容阅读
目的观察阿司匹林与双嘧达莫预防缺血性脑卒中复发的临床疗效及安全性。方法将172例缺血性脑卒中患者随机分为观察组和对照组各86例,两组均给予常规康复治疗。观察组在此治疗基础上给予肠溶阿司匹林及双嘧达莫治疗;对照组则口服双嘧达莫,疗程均为1年。比较两组脑卒中复发率、生存质量、生活活动能力、血液流变学变化及不良反应。结果观察组脑卒中复发率为8.1%,明显低于对照组的19.8%(P<0.05);观察组患者生活质量指数明显高于对照组(P<0.01);观察组生活活动能力明显优于对照组(P<0.01);观察组血液流变学较对照组明显改善(P<0.01)。两组患者均未出现明显不良反应。结论联合应用阿司匹林与双嘧达莫预防脑卒中复发,能有效降低其复发率,提高患者生活活动能力和生活质量,安全性好,具有广阔的应用前景。
Objective To observe the clinical efficacy and safety of aspirin and dipyridamole in preventing recurrence of ischemic stroke. Methods A total of 172 patients with ischemic stroke were randomly divided into observation group and control group, with 86 cases in each group. Both groups were given routine rehabilitation. The observation group was given enteric-coated aspirin and dipyridamole on the basis of this treatment. The control group was given dipyridamole orally for 1 year. The relapse rate, quality of life, ability of living activities, hemorheological changes and adverse reactions in the two groups were compared. Results The recurrence rate of stroke in the observation group was 8.1%, which was significantly lower than that in the control group (19.8%, P <0.05). The quality of life index of the observation group was significantly higher than that of the control group (P <0.01) (P <0.01). The blood rheology of the observation group was significantly improved compared with the control group (P <0.01). No significant adverse reactions occurred in both groups. Conclusions Combination of aspirin and dipyridamole to prevent the recurrence of stroke can effectively reduce the recurrence rate and improve the living activities and quality of life of patients with good safety and has broad application prospects.